Contact Us


OMICS has paved the way for incredible advances in the various fields of clinical, medical, drug discovery and development. These advances have provided insights to identify pathophysiology, understand drug interactions and develop personalized medicines. Read more
Immune or "convalescent” plasma refers to plasma collected from infected individuals, post resolution of infection. These infected individuals develop antibodies against the infection. Read more
Although three human coronaviruses namely: SARS-CoV, MERS-CoV, and SARS-CoV-2 have hit mankind in last two decades, no vaccines have yet been developed against them. Vaccines are the most effective strategy for preventing infectious disease including viral diseases like COVID-19. Read more
Growth in technology has been attributed to the strong association between computational power and Big Data. Data Management has been the corner stone for this evolution in the field of technology. Read more
 I have been involved with Excelra right from its inception in 2014 as part of the team that identified the original opportunity. Big data technology and analytics were starting to emerge as high growth areas, so we wanted to leverage these trends to serve the global life sciences industry. Read more
The conversion of unstructured data into high-quality actionable insights based on information retrieval, data mining, machine learning, statistics, and computational linguistics is commonly referred to as text mining. Read more
Reports suggest that SARS-CoV-2 virus has the ability to directly infect human blood vessel and kidney organoids. The use of clinical-grade recombinant human ACE2 (rhACE2) can reduce SARS-CoV-2 infection in cells and multiple human organoid models. Read more
G protein-coupled receptors (GPCRs) have become a hot frontier in basic research of life sciences and therapeutic discovery of translational medicines and is widely pursued by both academic and industrial research for drug discovery. They represent an important opportunity for both small molecule-based and antibody-based therapeutics and are the largest family of targets for approved drugs. Read more
GOSTAR is the largest manually annotated structure-activity relationship (SAR) database of small molecules published in leading medicinal chemistry journals and patents. Compounds from both discovery and development stages targeting all target families are covered. Along with SAR, key properties like ADME and toxicity are captured. Read more
In medicinal chemistry, the relationship between molecular structure of a compound and its biological activity is referred to as Structure Activity Relationship (SAR). Medicinal chemists modify biomedical molecules by inserting new chemical groups into the compound and test those modifications for their biological effects. Read more